Boston Scientific Co. (NYSE:BSX) SVP Maulik Nanavaty sold 23,458 shares of the stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $37.28, for a total value of $874,514.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NYSE:BSX opened at $34.60 on Thursday. The company has a market capitalization of $47.12 billion, a PE ratio of 23.81, a P/E/G ratio of 2.24 and a beta of 0.68. Boston Scientific Co. has a 1 year low of $24.54 and a 1 year high of $39.44. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.78 and a quick ratio of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.01. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.40 billion. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the company earned $0.31 EPS. Research analysts expect that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

Several analysts recently issued reports on BSX shares. Jefferies Financial Group upgraded Boston Scientific from a “hold” rating to a “buy” rating and increased their target price for the stock from $34.00 to $42.00 in a research report on Tuesday, September 4th. Barclays initiated coverage on Boston Scientific in a research note on Monday, October 15th. They set an “overweight” rating and a $43.00 price target for the company. Morgan Stanley increased their price target on Boston Scientific from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, October 2nd. Wells Fargo & Co increased their price target on Boston Scientific from $38.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Finally, Needham & Company LLC reissued a “strong-buy” rating and set a $43.00 price target (up from $39.00) on shares of Boston Scientific in a research note on Friday, September 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $39.32.

Several large investors have recently bought and sold shares of BSX. Captrust Financial Advisors lifted its stake in shares of Boston Scientific by 103.8% in the 2nd quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 1,594 shares during the last quarter. Quad Cities Investment Group LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $104,000. Kaizen Advisory LLC lifted its stake in shares of Boston Scientific by 146.7% in the 2nd quarter. Kaizen Advisory LLC now owns 3,299 shares of the medical equipment provider’s stock valued at $108,000 after purchasing an additional 1,962 shares during the last quarter. Moody National Bank Trust Division bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $108,000. Finally, Capital Guardian Trust Co. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $110,000. 92.27% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Boston Scientific Co. (BSX) SVP Maulik Nanavaty Sells 23,458 Shares” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2018/11/22/boston-scientific-co-bsx-svp-maulik-nanavaty-sells-23458-shares.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Further Reading: Fiduciary

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.